|D001261||Pulmonary Atelectasis NIH||1.00|
|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
COVID-19 originated from Severe Acut Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection leads to critical condition due to hypoxemic respiratory failure with the background of viral pneumonia. Both alevolar recruitment and the subsequent optimal positive end-expiratory pressure (PEEP) adjustment has a pivotal role in the elimination of atelectasis developed by inflammation in the lung parenchyma The gold standard of the follow up of recruitment manoeuvre is the chest computed tomography (CT) examination. However, reduction of intrahospital transport and the exposure with healthcare workers are recommended because of the extremely virulent pathogen spreading easily by droplet infection. In this case bedside investigations have an utmost importance in the management of hygiene regulations. Electric impedance tomography (EIT) is a non-invasive, radiation free functional imaging technique easily applicable at the bedside.
Description: Estimation of change in compliance (ml/cmH2O) from the beginning to end of of the incremental/decremental PEEP alveolar recruitment.Measure: Changes in lung compliance Time: 20 minutes
Description: Estimation of change in global impedance (%) from the beginning to end of of the incremental/decremental PEEP alveolar recruitment.Measure: Change in global impedance Time: 20 minutes
Description: Estimation of change in global impedance (%) on a daily manner.Measure: Change in recruitability Time: 7 days
Description: Change in arterial partial pressure of oxygen (PaO2) (mmHg) following recruitmentMeasure: Gas exchange Time: 20 minutes and 7 days
Description: Change in plateau pressure (cmH2O) following recruitmentMeasure: Plateau pressure Time: 20 minutes and 7 days
Description: Change in end expiratory lung impedance (%)Measure: End expiratory lung impedance (EELI) Time: 20 minutes and 7 days
Description: Change in antero-to-posterior ventilation ratio (%) following interventionMeasure: Antero-to-posterior ventilation ratio Time: 20 minutes and 7 days
Description: Change in center of ventilation (%) following interventionMeasure: Center of ventilation Time: 20 minutes and 7 days
Description: Change in global inhomogeneity index (%) following interventionMeasure: Global inhomogeneity index Time: 20 minutes and 7 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports